MARKET

NVAX

NVAX

Novavax
NASDAQ

Real-time Quotes | Nasdaq Last Sale

94.36
-1.94
-2.01%
After Hours: 94.38 +0.02 +0.02% 18:14 07/10 EDT
OPEN
94.00
PREV CLOSE
96.30
HIGH
98.61
LOW
93.51
VOLUME
3.07M
TURNOVER
--
52 WEEK HIGH
111.77
52 WEEK LOW
3.540
MARKET CAP
5.47B
P/E (TTM)
-22.7747
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NVAX stock price target is 115.00 with a high estimate of 148.00 and a low estimate of 101.00.

EPS

NVAX News

More
The U.S. Is Bailing Out Companies. Regeneron Doesnt Need the Help.
Barrons.com · 5h ago
Can Novavax Win FDA Approval for COVID-19 Vaccine Before Year End? Analyst Weighs In
TipRanks · 21h ago
U.S. planning for tens of millions of potential COVID-19 vaccine doses this fall - official
Reuters · 1d ago
Biotech Stocks Get a Boost
Motley Fool · 1d ago
Is It Too Late to Buy Novavaxs Stock?
Motley Fool · 1d ago
Is Vaxart Stock a Buy?
MotleyFool.com · 1d ago
Why Novavax Is Outperforming Moderna
Seeking Alpha - Article · 2d ago
Stock market news live updates: Stocks trade higher as Apple, Amazon hit record levels
Stocks were mixed Wednesday as investors weighed the economic impacts of the ongoing rise in coronavirus cases globally, and considered a report that raised further concerns over US-China tensions.
Yahoo Finance · 2d ago

Industry

Biotechnology & Medical Research
-0.77%
Pharmaceuticals & Medical Research
-0.48%

Hot Stocks

Symbol
Price
%Change

About NVAX

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).
More

Webull offers kinds of Novavax, Inc. stock information, including NASDAQ:NVAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVAX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVAX stock methods without spending real money on the virtual paper trading platform.